Aclarion, Inc. (NASDAQ:ACON) Sees Significant Growth in Short Interest

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 247,100 shares, an increase of 1,730.4% from the January 31st total of 13,500 shares. Based on an average daily trading volume, of 378,900 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

Several research firms have commented on ACON. Ascendiant Capital Markets lowered their target price on shares of Aclarion from $502.50 to $435.50 and set a “buy” rating on the stock in a research note on Wednesday, November 27th. Maxim Group reissued a “hold” rating on shares of Aclarion in a research note on Friday, December 13th.

Aclarion Stock Performance

NASDAQ:ACON opened at $2.63 on Friday. Aclarion has a twelve month low of $2.43 and a twelve month high of $231.15. The company has a 50-day moving average of $16.45 and a 200-day moving average of $46.02.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.